Abstract
Prognosis in cases of erythrocyte immunisation has improved continuously over the past decades. Morbidity and mortality have been reduced by improvements in management, including screening programmes, non-invasive ultrasound evaluation and invasive procedures. The article provides an outline of the latest developments in the management of erythrocyte immunisation, and several controversial issues are discussed, such as antibody screening, strategies for the reduction of antibody titres, and the organisation of care.
MeSH terms
-
Anemia, Neonatal / etiology
-
Anemia, Neonatal / prevention & control
-
Anemia, Neonatal / therapy
-
Antibodies / analysis
-
Centralized Hospital Services
-
Erythroblastosis, Fetal / diagnosis
-
Erythroblastosis, Fetal / genetics
-
Erythroblastosis, Fetal / prevention & control
-
Erythrocyte Transfusion
-
Erythrocytes / immunology*
-
Female
-
Humans
-
Infant, Newborn
-
Mass Screening
-
Pregnancy
-
Prognosis
-
Regional Medical Programs
-
Rh Isoimmunization* / diagnosis
-
Rh Isoimmunization* / genetics
-
Rh Isoimmunization* / prevention & control